Going straight to the angiography suite for suspected large vessel stroke
Compares going directly to the angiography suite with CT or MRI first in suspected stroke.
Plain-language title generated from the registry record
Registry title: Advancing Reperfusion Therapy for Ischemic Stroke: Direct Transfer to Angiography Suite for Patients With Suspected Large Vessel Occlusion
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected large vessel blockage stroke who arrive within 6 hours of symptom onset. It compares going straight to the angiography suite with the usual CT/MRI scan first.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Signs of a sudden large vessel blockage stroke; randomization within 6 hours of symptom onset; NIHSS score of 10 or more before randomization.
- Earlier treatment
- No prior treatment required. People who took part in other interventional trials in the past 3 months cannot join.
Main reasons for not taking part
- Refuses endovascular treatment
- Allergy to contrast agents
- Signs of bleeding inside the skull
- Transferred from a center without thrombectomy capability
- Pregnant, nursing, or positive pregnancy test
Read by machine on 9 November 2026.
Where in China
- Beijing Tiantan HospitalBeijing, ChinaContact: Yunyun XiongNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07460713
- Record updated
- 12 March 2026
- Original description
The investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MRI in patients with suspected large artery occlusive (LVO) within 6 hours of symptom onset.Read full original descriptionShow less
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Direct Transfer to Angiography Suite (DTAS) for Patients With Suspected Large Vessel Occlusion
The investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MRI in patients with suspected large artery occlusive (LVO) within 6 hours of symptom onset.
Inclusion: Age≥18 years old; Patients presenting with symptoms or signs suggestive of acute large vessel occlusion (LVO) stroke；; Randomization within 6 hours of symptom onset；; Baseline NIHSS score ≥10 points prior to randomization; Pre-stroke modified Rankin Scale (mRS) score ≤2; Written informed consent from patients or their legally authorized representatives.
Exclusion: Participation in other interventional clinical trials within the previous 3 months; Allergy to contrast agents; Clinical symptoms or signs suggestive of intracranial hemorrhage (e.g., severe headache, seizures, or signs of increased intracranial pressure); Seizure at stroke onset, postictal paralysis, or inability or unwillingness to cooperate due to epilepsy or other neurological or psychiatric disorders; Clinically unstable conditions requiring urgent life-support treatment; Any terminal illness such that the patient would not be expected to survive more than 1 year; Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study; Refusal of endovascular treatment；; Transferred patients (e.g., from centers without thrombectomy capability); Other standard contraindications to endovascular treatment; Pregnant women, nursing mothers, or women with a positive pregnancy test at admission; Unlikely to adhere to the trial protocol or follow-up.